23andMe (ME) Q4 2025 earnings summary

Executive summary

• Entered into an Asset Purchase Agreement on May 17, 2025, to sell substantially all assets to Regeneron Pharmaceuticals for $256 million, subject to bankruptcy court approval and closing conditions.

• Filed for Chapter 11 bankruptcy on March 23, 2025, and continued operations as debtors-in-possession, seeking to maximize value for stakeholders.

• The sale excludes the telehealth business (Lemonaid Health), which will be wound down post-closing.

• If the Regeneron transaction is not completed, a backup bid from TTAM Research Institute for $305 million is in place.

Financial highlights

• Purchase price for the asset sale is $256 million in cash, plus assumption of certain liabilities and cure payments.

• Regeneron made a $25.6 million earnest deposit; TTAM submitted a higher bid of $305 million, triggering a new round of bidding.

• The company has a $60 million DIP (debtor-in-possession) credit facility with JMB Capital Partners, bearing 14% interest, maturing September 30, 2025.

Outlook and guidance

• The transaction is subject to bankruptcy court approval, antitrust clearance, and customary closing conditions, with a hearing scheduled for June 17, 2025.

• If the sale to Regeneron is not consummated, the company will seek court approval to proceed with TTAM's bid.

• Management continues to express substantial doubt about the company's ability to continue as a going concern.